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has been implicated in the pathogenesis of sepsis. We recently
demonstrated that ET-1 plays an important role in the development
of ALI in a rat model of sepsis. As an extension of recent study, in this
investigation we investigated whether landiolol hydrochloride, an
ultra- short-acting β-blocker, can play an important role in
ameliorating LPS-induced ALI through the normalization of ET-1.
Male Wistar rats at 8 weeks of age were administered with either
saline or lipopolysaccharide (LPS) for 3 h and some LPS-administered
rats were continuously treated with landiolol for 3 h. The features of
acute lung injury were observed at sepsis model. At 3 h after LPS
administration, both circulatory and pulmonary TNF-α levels
increased and PaO2 signiﬁcantly decreased LPS administration. LPS
induced a time-dependent expression of ET-1 in the lungs compared
to control, peaking and increasing by 3 fold at 6 h after induction of
endotoxemia, whereas levels of ET (B) receptor, which has
vasodilating effects, were remarkably down regulated time-depen-
dently. We conclude that time-dependent increase of ET-1 and ET
(A) receptor with the down regulation of ET (B) receptor may play a
role in the pathogenesis of acute lung injury in endotoxemia. Finally,
treatment of LPS-administered rats with landiolol for 3 h failed to
normalize the upregulated pulmonary ET-1 and TNF-α levels.
Another study found that landiolol can ameliorate ALI in LPS-induced
sepsis model. These data taken together, led us to conclude that
landiolol mediated ALI improvement in sepsis does not involve
pulmonary ET system.
doi:10.1016/j.lfs.2014.01.013
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Background: Expression of transient receptor potential subfamily C
(TRPC) 6, receptor-operatedCa2+channels, is increased in hypertrophic
and failing hearts. TRPC6 has been shown to be a positive regulator of
calcineurin-NFAT signaling that drives pathological cardiac remodeling.
In this study we examined the effect of TRPC inhibition on the
pathological cardiac hypertrophy. Methods and results: In cultured
neonatal rat ventricular myocytes, overexpression of TRPC6 increased
basal and ET-1 inducedNFAT-dependent RCAN1promoter activity. BTP2,
a selective TRPC channel blocker, signiﬁcantly and dose-dependently
inhibited activation of the RCAN1 promoter, and attenuated hypertro-
phic response of cultured cardiac myocytes. Knocking-down of TRPC6
and 3 using siRNAs signiﬁcantly inhibited ET-1- or Ang II-induced
increases in Ca2+ oscillation, and knocking down either TRPC6 or 3 had a
similar effect. In model mice lacking GC-A, which is a common receptor
for atrial and brain natriuretic peptides, the expression of TRPC6 and
RCAN1 was increased and BTP2 signiﬁcantly attenuated the cardiac
hypertrophy observed inGC-AKOmicewithout affecting blood pressure.
BTP2 also inhibited AngII-induced cardiac hypertrophy in mice. Com-
patible with the notion that TRPC6 and 3 form heteromultimeric cation
channels, Pyrazole-3, a selective TRPC3 blocker, which can inhibit the ion
channel activity of TRPC3/6 hetero-complex, also signiﬁcantly inhibited
Ang-II induced cardiac hypertrophy in mice. Conclusions: Blockade of
TRPC6 could be a novel therapeutic strategy for preventing pathological
cardiac remodeling.
doi:10.1016/j.lfs.2014.01.014
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Landiolol, an ultra-short-acting and highly cardioselective beta-1
blocker, has become useful for various medical problems. Recent studies
have demonstrated that co-treatment with landiolol protects against
acute lung injury and cardiac dysfunction in a rat model of lipopolysac-
charide (LPS)-induced systemic inﬂammationwhichwas associatedwith
a signiﬁcant reduction in serum levels of the inﬂammation mediator
HMGB-1 and histological lung damage. Endothelin (ET)-1, a potent
vasoconstrictor, has been implicated in the pathogenesis of sepsis and
sepsis-induced multiple organ dysfunction syndrome. In the current
study, we investigated whether landiolol hydrochloride can play an
important role in ameliorating the LPS-induced altered cardiac ET system
in a rat model of endotoxemia. Male Wistar rats at 8 weeks of age
were administered LPS for 3 h and some LPS-administered rats were
continuously treated with landiolol for three hours. At 3 h after LPS
administration, circulatory TNF-alpha level was highly increased. Blood
lactate concentration and percentage of fractional shortening of heart
have also signiﬁcantly increased after LPS administration. In addition, LPS
induced a signiﬁcant upregulated expression of various components of
ET-1 system in the cardiac tissues compared to control. Finally, treatment
of LPS-administered ratswith landiolol for 3 h potentially normalized the
increased blood lactate level, cardiac functional compensatory events
without an effect on plasma TNF-alpha and ET-1 levels. Most strikingly,
landiolol treatment has greatly normalized the various components of
ET-1 system in endotoxemic heart. These data taken together, led us to
conclude that landiolol may be cardio protective in endotoxemia
normalizing the vasoactive peptide like endothelin without altering the
circulatory level of potential inﬂammatory cytokine like TNF-alpha.
doi:10.1016/j.lfs.2014.01.015
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Growing body of evidences state the cardiovascular beneﬁt of
ﬁsh oil including eicosapentaenoic acid (EPA) in humans and experi-
mental animals, but the effect of EPA on endothelin (ET)-1-induced
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cardiomyocyte hypertrophy is unknown. Previous study demon-
strated that peroxisomal proliferator-activated receptor (PPAR)-α
ligand (fenoﬁbrate) prevents ET-1-induced cardiomyocyte hyper-
trophy. Though EPA is a ligand of PPAR-α, there was no study linking
relationship between EPA and PPAR-α in the ﬁeld of cardiomyocyte
hypertrophy. The present study investigated whether ET-1-induced
cardiomyocyte hypertrophy could be prevented by EPA pre-treatment
with possible mechanistic insights. At day 4 of culture, neonatal rat
cardiomyocytes were divided into three groups: control, ET-1 (0.1 nM)
treated and EPA-pre-treated (10 μM) ET-1 groups. 2-fold increase in
cardiomyocyte surface area, 1.8-fold increase in total protein synthesis
rate and an enhanced α-actinin expression in cardiomyocyte were
observed after ET-1 administration and these changes were greatly
prevented by EPA pre-treatment. ET-1-induced hypertrophied cardio-
myocytes showed increases in ANP and BNP mRNA expression, which
were also suppressed by EPA pre-treatment. Pre-treatment of EPA could
also attenuate phosphorylated JNK (an important component of MAPK
cascade) and c-Jun (downstream molecules of JNK) in ET-1-induced
hypertrophied cardiomyocytes. PPAR-α expression and PPAR-PPRE
binding activity were suppressed in ET-1 administered cardiomyocyte
and this suppressionwas improvedbyEPA treatment. In conclusion, the
present study showed that ET-1 could induce signiﬁcant cardiomyocyte
hypertrophy with hypertrophic markers upregulation, and that this
remodeling was effectively prevented by EPA-pre-administration
through the upregulation of PPAR-α and the suppression of phosphor-
ylated JNK, and c-Jun.
doi:10.1016/j.lfs.2014.01.016
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Objective: Endothelins are powerful vasoconstrictor peptides that
also play numerous other functions in many different organs.
Endothelin-1 (ET-1) is the most abundant and important of this
family of peptides in blood vessels. ET-1, a potential marker of
endothelial dysfunction has been shown in hypertensive subjects. No
study yet has investigated the circulatory level of ET-1 in a country
from South Asia. The present study assessed circulating levels of ET-1
in subjects with or without hypertension and further examined
their association with clinical and metabolic parameters. Methods
and results: A total of 1802 rural Bangladeshi women with mean age
of 44.16 yearswere studiedusing a cross-sectional survey. Theprevalence
of hypertension was 31.78%. Endothelin-1 levels were signiﬁcantly
higher in hypertensive than in non-hypertensive subjects (hypertensive
vs non-hypertensive: 4.16 ± 0.32 vs. 3.00 ± 0.08 pg/ml, p b 0.001). After
adjusting for age, ET-1 had signiﬁcant positive associations with diastolic
blood pressure (DBP) (β=0.039, p = 0.013) and systolic blood pressure
(SBP) (β=0.020, p = 0.006). Unlike blood pressures, other variables
including insulin, fasting blood glucose, triglycerides, high-density
lipoprotein cholesterol, body mass index, waist circumference and
vascular endothelial growth factor were not associated with ET-1.
Stepwise multiple regression analysis, after adjusting for age and all
other potential variables revealed that SBP and DBP were independent
determinants of ET-1. Conclusions: The correlation of ET-1 needs
further investigations to deﬁne the clinical utility and predictive value
of serumET-1 levels in hypertension for South Asian population. Higher
concentration of ET-1 suggests endothelial dysfunction already in mild
forms of hypertension without further risk factors or cardiovascular
complications in this apparently healthy population.
doi:10.1016/j.lfs.2014.01.017
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Patients with ASD have increased pulmonary blood ﬂow and may
cause increase in pulmonary arterial pressure. Endothelin-1 (ET-1)
mainly produced by pulmonary vascular endothelium and increased
plasma ET-1 level has been reported in patients with left-to-right
shunt. ASD is the most common congenital shunting in adult.
However, no study addressed speciﬁcally for ASD and has evaluated
the role of ET-1 in this congenital shunting. Therefore, we aim to
correlate the peripheral ET-1 level with pulmonary arterial pressure in
adult patients with uncorrected ASD. From July 2012–April 2013 we
enrolled 55 ASD patients; mean age 34.5 years-old. Conﬁrmation of
ASD and the measurement for pulmonary arterial pressure (mPAP),
right ventricular systolic pressure (RVSP), and pulmonary ﬂow ratio
(Qp/Qs) were performed using TTE and TEE. These measure-
ments were previously conﬁrmed with right heart cathetherization
and showed positive correlation (r = 0.5; p b 0.0001 and r = 0.8;
p b 0.0001 respectively). Peripheral blood was withdrawn from
brachial vein. Forty (72%) patients have left-to-right and 28% with
right-to-left shunting. Mean mPAP was 40.1 ± 14.9 mm Hg; mean
circulating ET-1 was 5.6 ± 2.1 pg/dl. Unexpectedly, the correlation
between circulating level of ET-1 andmPAPwas signiﬁcantly inversed
(r = -0.452;p b 0.01), and with RVSP was also signiﬁcantly negative
(r = -0.405;p b 0.01). Accordingly, the reduced circulating ET-1 level
might be explained by the decrease in Qp/Qs (r = 0.310;p b 0.05).
However, no differences of ET-1 were found between LtoR vs
RtoL shunts (5.7 ± 0.36vs.5.3 ± 0.52 pg/dl; NS). As a conclusion, we
observed inversed relationship between circulating ET-1 and
mPAP that might partially be explained by the decreased in pulmonary
ﬂow. Further study to elucidate whether pulmonary derived ET-1 may
play more roles in this disease is needed.
doi:10.1016/j.lfs.2014.01.018
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